Prieur A M, Adleff A, Debre M, Boulate P, Griscelli C
Immunologie et Rhumatologie Pédiatriques, INSERM U 132, Hôpital des Enfants-Malades, Paris, France.
Clin Exp Rheumatol. 1990 Nov-Dec;8(6):603-8.
Sixteen children with severe juvenile chronic arthritis received high dose intravenous immunoglobulin (IVGG). Extra-articular symptoms improved to some degree in 6 of ten patients. A decrease in the number of active joints occurred in 7 patients of the 11 who received more than ten months of IVGG. Hemoglobin levels increased, the ESR and platelet counts decreased and the IgG levels diminished in most of the patients who received long term treatment. The treatment was totally ineffective in three children who had very severe disease. Two children had respectively a vasculitic rash and urticaria thought to be side effects of the treatment. One had proteinuria. This last might have been due to other therapeutic agents given. Although clinical and biological benefits occurred in some, the state of the patients who had short term (m = 2-3 months) or long term (m = 2-7 years) therapy was not different at the last visit.
16名患有严重幼年型慢性关节炎的儿童接受了大剂量静脉注射免疫球蛋白（IVGG）治疗。10名患者中有6名的关节外症状有一定程度改善。在接受超过10个月IVGG治疗的11名患者中，7名患者的活动关节数量减少。大多数接受长期治疗的患者血红蛋白水平升高，血沉和血小板计数降低，IgG水平下降。该治疗对3名病情非常严重的儿童完全无效。2名儿童分别出现血管炎性皮疹和荨麻疹，被认为是治疗的副作用。1名儿童出现蛋白尿。这最后一种情况可能是由于使用了其他治疗药物。尽管部分患者出现了临床和生物学益处，但在最后一次随访时，接受短期（m = 2 - 3个月）或长期（m = 2 - 7年）治疗的患者状况并无差异。
